ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program

ADC Therapeutics said ZYNLONTA plus glofitamab achieved an 88.7% overall response rate and 75.3% complete response rate among 97 efficacy-evaluable patients with relapsed/refractory DLBCL in Phase 1b LOTIS-7 data. A Phase 2 investigator-initiated trial abstract reported a 93% overall response rate and 74.4% complete response rate with ZYNLONTA monotherapy in marginal zone lymphoma. The data are scheduled for presentation at the ASH Annual Meeting on December 12–15, 2026.

Analysis

The read-through is strategically useful but not yet a change in ADCT’s earnings base. If the combination signal survives fuller review, ZYNLONTA could become more relevant in treatment pathways alongside bispecific antibodies such as glofitamab; that may support partnering or combination-development value, but it also makes tolerability, treatment sequencing, and commercial economics decisive. The monotherapy lymphoma result could broaden the addressable opportunity, but an investigator-initiated Phase 2 study is not evidence of registrational readiness or a near-term label expansion.

The immediate risk is that investors capitalize response rates before seeing cohort characteristics, follow-up, duration of response, safety, and discontinuations. Cross-trial comparisons would be especially unreliable. The December ASH abstracts are the next verifiable catalyst; the company call may move sentiment sooner, but management commentary is not a substitute for complete data. Over 6–18 months, the key value drivers are confirmatory development, regulatory alignment, and whether added use can translate into durable commercial uptake without undermining tolerability.

Contrarian view: high response rates are attention-grabbing, but they can obscure small-study selection effects and limited durability evidence. Conversely, if responses prove deep and durable with manageable toxicity, the market may be underestimating ZYNLONTA’s option value beyond its established commercial setting. No valuation, price action, or cash-runway data are provided, so the release alone does not justify sizing a directional position.

Key Decisions for Investors

• Do not chase an immediate ADCT rally solely on the topline response rates. Review the call and December abstracts for evaluable-patient definitions, follow-up, duration of response, safety, and discontinuations.
• Treat ADCT as a catalyst watch rather than a high-conviction long until fuller data and development plans are available. Reassess after ASH against the current share price, valuation, and cash runway.
• A bullish thesis is strengthened by durable responses and manageable toxicity across the disclosed cohorts; it is weakened by short follow-up, material discontinuations, or no credible confirmatory/regulatory path.
• Monitor whether combination use complements or competes with bispecific-antibody treatment pathways. Any commercial opportunity remains conditional on sequencing, access, and evidence beyond these early or investigator-led datasets.